

4 October 2011

President Ruth J. Simmons  
Office of the President  
Brown University  
1 Prospect Street  
Campus Box 1860  
Providence, Rhode Island 02912

Dear President Simmons,

**Study 329: A multi-center, double blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression**

We write to you about our ongoing concerns regarding a journal article that originated at the Department of Psychiatry and Human Behavior, under the leadership of Dr. Martin Keller.

Between 1993 and 1998, SmithKline Beecham (subsequently GlaxoSmithKline) provided \$800,000 to Brown University for its participation in the above study.<sup>[1]</sup> The results were published in 2001 by Keller et al. in a journal article, 'Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial',<sup>[2]</sup> in the *Journal of the American Academy of Child & Adolescent Psychiatry*.

The article was ghostwritten by agents of the manufacturer, and seriously misrepresented both the effectiveness and the safety of paroxetine in treating adolescent depression.

While problems with study 329 and the Keller et al paper have been thoroughly exposed in legal actions,<sup>[3]</sup> the bioethical and medical literature,<sup>[4]</sup> a book,<sup>[5]</sup> and a BBC Panorama documentary<sup>[6]</sup>, the paper continues to be cited uncritically in the medical literature as evidence of the efficacy of paroxetine for treatment of adolescent depression.<sup>[7],[8]</sup> Our main concern is that adolescents are being harmed because well-intentioned physicians have been misled.

Moreover, the misrepresentation has been compounded by the following:

- 1) The *Journal* was asked by two of the undersigned, Drs. Jureidini and McHenry, to retract the article, but has refused to do so.
- 2) In a letter of May 13, 2008, from Pamela D. Ring to Dr. David Egilman, Brown University refused to release information about its internal investigation into Dr. Keller's conflicts of interest and scientific misconduct.

Study 329 reveals the pervasive influence of GlaxoSmithKline's marketing objectives on the preparation and publication of a 'scientific' manuscript and peer-reviewed journal article. GlaxoSmithKline's own internal documents disclosed in litigation show that company staff were aware that the study 329 did not support a claim of efficacy but decided that it would be "unacceptable commercially" to reveal that.<sup>[9]</sup>

The data were therefore selectively reported in Keller *et al.*'s article, in order to "effectively manage the dissemination of these data in order to minimise any potential negative commercial impact".<sup>9</sup> As it turns out, the Keller *et al.* article was used by GlaxoSmithKline's to ward off potential damage to the profile of paroxetine and it was used to promote off-label prescriptions of Paxil® and Seroxat® to children and adolescents, some of whom became suicidal and self-harmed as a result.<sup>[10]</sup>

The unretracted article is a stain on Brown University's reputation for academic excellence. The University cannot claim to be a leader in scientific research and moral integrity while failing to act to redress this article that negligently misrepresents scientific findings.

In its accreditation document for the New England Association of Schools and Colleges (NEASC), Brown University claims in relation to 'Standard Eleven: Integrity' that 'The institution manages its academic, research and service programs, administrative operations, responsibilities for students and interactions with prospective students with honesty and integrity', that it 'expects

that members of its community, including the board, administration, faculty, staff, and students, will act responsibly and with integrity', and that 'Truthfulness, clarity, and fairness characterize the institution's relations with all internal and external constituencies'.<sup>[11]</sup> The University's inaction in relation to study 329 casts doubt on the validity of these claims.

We ask that you write to the editor, Dr. Andrés Martin, *Journal of the American Academy of Child & Adolescent Psychiatry* supporting our request for retraction of the journal article.

We are making this letter available to interested parties and it will be posted on the Healthy Skepticism website ([www.healthyskepticism.org](http://www.healthyskepticism.org)).

Yours sincerely

Jon Jureidini  
Child Psychiatrist  
Clinical Professor, University of Adelaide

Leemon McHenry  
Department of Philosophy, California State University, Northridge

Jerome Biollaz  
Professor Emeritus of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne

Alain Braillon

Stephen Bezruchka  
Senior Lecturer, School of Public Health, University of Washington

Ruud Coolen van Brakel, director  
Sandra van Nuland, consultant  
Martine van Eijk, MD PhD  
Instituut voor Verantwoord Medicijngebruik (*Dutch Institute for Rational Use of Medicine*)

Marc-André Gagnon,  
Research Fellow, Edmond J. Safra Center for Ethics, Harvard University

Ken Harvey  
Adjunct Senior Lecturer, School of Public Health, La Trobe University, Melbourne

David Healy  
Professor in Psychological Medicine, Cardiff University School of Medicine

Andrew Herxheimer,  
Emeritus Fellow, UK Cochrane Centre, Oxford

Jerome Hoffman  
Professor of Emergency Medicine, University of Southern California

Joel Lexchin  
Professor, School of Health Policy and Management, York University, Toronto, Canada

Melissa Raven  
Adjunct Lecturer, Discipline of Public Health, Flinders University, Australia

Dee Mangin  
Associate Professor, Director Primary Care Research Unit, Christchurch School of Medicine

Peter Mansfield  
Director, Healthy Skepticism

Dan Mayer  
Professor of Emergency Medicine, Albany Medical College, New York

David Menkes  
Associate Professor of Psychiatry, University of Auckland

Robert Purssey  
Senior Lecturer, University of Queensland

Nicholas Rosenlicht  
Clinical Professor of Health Sciences, University of California, San Francisco

Jörg Schaaber  
President, International Society of Drug Bulletins (ISDB)

Arthur Schafer  
Director, Centre for Professional and Applied Ethics, University of Manitoba

Michael Wilkes  
Professor of Medicine, University of California, Davis

Jim Wright  
Co-Managing Director, Therapeutics Initiative

Liliya E. Ziganshina  
Head, Professor, Department of Basic and Clinical Pharmacology, Kazan Federal University,  
Russian Federation